However, it has been reported that patients with nonalcoholic steatohepatitis (NASH)-mediated liver cancer may not benefit from anti-PD1 treatment; besides, NASH-related aberrant T-cell activation is a potential cause [6]. This evidence concerns the gene PDCD1 and metabolic dysfunction-associated steatohepatitis.